9x7u: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Complex of HLA-A2, a class I MHC, with a UTP20 peptide== | |||
<StructureSection load='9x7u' size='340' side='right'caption='[[9x7u]], [[Resolution|resolution]] 1.59Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[9x7u]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=9X7U OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=9X7U FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.59Å</td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=9x7u FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=9x7u OCA], [https://pdbe.org/9x7u PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=9x7u RCSB], [https://www.ebi.ac.uk/pdbsum/9x7u PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=9x7u ProSAT]</span></td></tr> | |||
</table> | |||
== Function == | |||
[https://www.uniprot.org/uniprot/Q8WLS4_HUMAN Q8WLS4_HUMAN] | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Adoptive T cell therapy (ACT) eliminates tumors by infusing tumor reactive T cells. Neoantigens from somatic mutations are ideal targets due to their absence in normal tissues. How charge-reversing mutations drive neoantigen immunogenicity remains unclear. Here, we determined the wild-type and mutant UTP20-HLA-A2 structures and found them nearly identical except at the mutation site (Asp to His). The TCR-pHLA structure revealed selective recognition through specific interactions between CDR loops and the mutation site. Rosetta calculations showed that His provides favorable interactions absent in the wild-type. TCR engagement also induced a flip of the P6 side chain, reshaping the interface. These findings provide a structural basis for charge-reversed mutation-driven T cell responses and inform neoantigen-based ACT development. | |||
Structural basis for CD8(+) T cell recognition of the charge-reversed neoantigen UTP20(D2661H).,Wang J, Li S, Mao L, Yang D, Yao Z, Shi J, He W, Wu D J Struct Biol. 2026 Sep 11;218(4):108371. doi: 10.1016/j.jsb.2026.108371. PMID:42727733<ref>PMID:42727733</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
[[Category: | <div class="pdbe-citations 9x7u" style="background-color:#fffaf0;"></div> | ||
[[Category: Wang | == References == | ||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Homo sapiens]] | |||
[[Category: Large Structures]] | |||
[[Category: Wang J]] | |||
[[Category: Wu DC]] | |||
Latest revision as of 16:31, 25 September 2026
Complex of HLA-A2, a class I MHC, with a UTP20 peptide
| ||||||||||||